Based on the data from the previous project, the main objective of this project is to define the biomarkers particularly involved in the phenomena of tolerance, inflammation and rejection in order to improve the diagnostic and therapeutic management of transfused, transplanted patients as well as their donor selection.
Among these, circulating DNA appears to be a promising non-invasive biomarker of acute and chronic organ rejection and is analyzed quantitatively and qualitatively in an innovative way through partnerships with CareDX and Adelis.
Similarly, the dissection of the mechanisms of toxicity of humoral and/or cellular alloimmunization directed against HLA antigens and non-HLA antigens of epithelial and endothelial cells constitutes an important clinical research axis.
This project is led by Julie Di Cristofaro (PhD, HDR, CR EFS), Christophe Picard, (MD, PhD, HDR, EFS) and Pascal Pedini (PharmD, PhD, EFS), it benefits from numerous collaborations, including that with the lung transplantation service directed by Pr Martine Reynaud Gaubert (APHM, C2VN).